Sep 30 2017
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Sevelamer Carbonate Tablets, 800 mg, a therapeutic equivalent generic version of Renvela® (sevelamer carbonate) Tablets, approved by the U.S. Food and Drug Administration (USFDA).
"We are very pleased to bring Sevelamer Carbonate Tablets to market at this time," says Alok Sonig, Executive Vice President and Head of the North America Generics business at Dr. Reddy's. "This launch represents Dr. Reddy's expertise and commitment to provide affordable alternatives for complex, limited-competition products to market." This is the Company's eighth overall and fourth limited-competition launch this fiscal year.
The Renvela® brand and generic had U.S. sales of approximately $1.88 billion MAT for the most recent twelve months ending in July 2017 according to IMS Health.
Dr. Reddy's Sevelamer Carbonate Tablets, 800 mg are available in the bottle count size of 270 tablets.
Renvela® is a trademark of Genzyme Corporation
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients